ATP13A2 and Parkinson disease: Experiments conducted in ATP13A2 PD patient-derived fibroblasts showed that ATP13A2 loss of function leads to several lysosomal alterations including impaired lysosomal acidification, decreased proteolytic processing of lysosomal enzymes, reduced degradation of lysosomal substrates and diminished lysosomal-mediated clearance of autophagosomes (Dehay et al. 2012).